Induced Fit Simulations on Nuclear Receptors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 133-147

  Nocker, Monika ^a   Cozzini, Pietro ^b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF PARMA   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Allosteric effect; Closed agonistic conformation; Helix H12 positioning; Ligand Binding Domain; Micro and macroscopic flexibility; Nuclear Receptor Superfamily; Open antagonistic conformation

Indexed keywords

4 HYDROXYTAMOXIFEN; ALDOSTERONE; ALITRETINOIN; AMINO ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; ASOPRISNIL; BICULATAMIDE; BMS 614; CYPROTERONE ACETATE; DEACYLCORTIVAZOL; DEXAMETHASONE; EM 5477; ESTRADIOL; ESTROGEN; GLUCOCORTICOID RECEPTOR; HYDROXYFLUTAMIDE; MIFEPRISTONE; MOMETASONE FUROATE; NORETHISTERONE; PEROXISOME PROLIFERATOR; PHENYLPYRAZOLOGLUCOCORTICOID CORTIVAZOL; PROGESTERONE; RALOXIFENE; SPIRONOLACTONE; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; WAY 244;

ALLOSTERISM; ARTICLE; COMPUTER SIMULATION; CRYSTALLOGRAPHY; DRUG STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 78649878888     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794863526     Document Type: Article

References (88)

1. Gronemeyer, H.; Gustafsson, J.-Å.; Laudet, V. Principles formodulation of the nuclear receptor superfamily. Nature, 2004, 3, 950-964.
2. Laudet, V.; Gronemeyer, H. The Nuclear Receptor Facts Book; SanDiego: Academic Press, 2001.
3. Bourguet, W.; Germain, P.; Gronemeyer, H.; Nuclear receptorligand-binding domains: three-dimensional structures, molecularinteractions and pharmacological implications. TiPS, 2000, 21, 381-388.
4. Bain, D. L.; Heneghan, A. F.; Connaghan-Jones, K. D.; Miura, M.T. Nu-clear receptor structure: Implications for function. Annu.Rev. Physiol., 2007, 69, 201-220.
5. Birnbaumer, M.; Schrader, W. T.; O'Malley, B. W. Assessment of structural similarities in chick oviduct progesterone receptorsubunits by partial proteolysis of photoaffinity-labeled proteins. J.Biol. Chem., 1983, 258, 7331-7337.
6. Wrange, O.; Okret, S.; Radojcic, M.; Carlstedt-Duke, J.; Gustafsson, J. A. Characterization of the puried activated glucocorticoidreceptor from ratliver cytosol. J. Biol. Chem., 1984, 259, 4534-4541.
7. McEwan, I.J.; Lavery, D.; Fischer, K.; Watt, K. Natural disorderedsequences in the aminoterminal domain of nuclear receptors: lessonsfrom the and rogen and glucocorticoid receptors. Nucl. ReceptorSignal., 2007, 5, 1-6.
8. Kumar, R.; Betney, R.; Li, J.; Thompson, E. B.; McEwan, I. J.Induced α-helix structure in AF1 of the and rogen receptor uponbinding transcription factor TFIIF. Biochemistry, 2004, 43, 3008-3013.
9. Brodie, J.; McEwan, I. J. Intra-domain communication between theN-terminal and DNA-binding domains of the and rogen receptor: modulation of and rogen response element DNA binding. J. Mol.Endocrinol., 2005, 34, 3008-3013.
10. Germain, P.; Staels, B.; Dacquet, C.; Spedding, M.; Laudet, V.Overview of nomenclature of nuclear receptors. Pharm. Rev., 2007, 59, 685-704.
11. Hard, T.; Kellenbach, E.; Boelens, R.; Maler, B. A.; Dahlman, K.; Freed-man, L. P.; Carlstedt-Duke, J.; Yamamoto, K. R.; Gustafsson, J. A.; Kaptein, R. Solution structure of the glucocorticoidreceptor DNA-binding domain. Science, 1990, 249, 157-160.
12. Baumann, H.; Paulsen, K.; Kovacs, H.; Berglund, H.; Wright A. P.Refined solution structure of the glucocorticoid receptor DNAbindingdomain. Biochemistry, 1993, 32, 13463-13471.
13. Khorasanizadeh, S.; Rastinejad, F. Nuclear-receptor interactions onDNA-response elements. Trends Biochem. Sci., 2001, 26, 384-390.
14. Cutress, M. L.; Whitaker, H. C.; Mills, I. G.; Stewart, M.; Neal, D.E. Structural basis for the nuclear import of the human and rogenreceptor. J. Cell Sci., 2008, 121, 957-968.
15. Bourguet, W.; Ruff, M.; Chambon, P.; Gronemeyer, H.; Moras, D.Crystal structure of the ligand binding domain of the human nucelarrecptor RXR-α. Nature, 1995, 375, 377-382.
16. Askew, E. B.; Gampe, Jr., R.T.; Stanley, T. B.; Faggart, J. L.; Wilson, E. M. Modulation of and rogen receptor activation function 2by testosterone and dihydrotestosterone. J. Biol. Chem., 2007, 282, 25801-15816.
17. Evans, R. M. The steroid and thyroid hormone receptor superfamily.Sciene, 1988, 240, 889-895.
18. Weatherman, R. V.; Fletterick R. J.; Scanlan, T. S. Nuclearreceptorligands and ligand-binding domains. Annu. Rev. Biochem., 1999, 68, 559-581.
19. Robinson-Rechavi, M.; Carpentier, A. S.; Duffraisse, M.; Laudet, V. How many nuclear hormone receptors are there in the humangenome? Trends Genetic., 2001, 17, 554-556.
20. Nuclear Receptor Nomenclature Committee: A unified nomenclaturesystem for nuclear receptor superfamily. Cell., 1999, 97, 161-163.
21. Paech, K.; Webb, P.; Kuiper, G. G. J. M., Nilsson, S.; Gustafsson, J.-Å. Differential ligand activation of estrogen receptors ER alphaand ER beta at AP1 sites. Science, 1997, 277, 1508-1510.
22. Dawson, M. I.; Chao, W.R.; Pine, P.; Jong, L.; Hobbs, P. D. Correlationof retinoid binding affinity to retinoic acid receptor α withretinoid inhibition of growth of estrogen receptor-positive MCF-7mammary carcinoma cells. Cancer Res., 1995, 55, 4446-4451.
23. Charpentier, B.; Bernardon, J. M.; Eustache, J.; Millois, C.; Martin, B. Synthesis, structure-affinity relationships, and biological activitiesof ligand binding to retinoic acid receptors subtypes. J. Med.Chem., 1998, 38, 4993-5006.
24. Taneja, R.; Roy, B.; Plassat, J. L.; Zusi, C, F.; Ostrowski, J. Celltypeand promoter-context dependent retinoic acid receptor (RAR)redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19cells can be artefactually generated by gene knockouts. Proc. Natl.Acad. Sci. USA, 1996, 93, 6197-6202.
25. Chiellini, G.; Apriletti, J. W.; Yoshihara, H. A.; Baxter, J.D.; Ribeiro, R. C. J. A high-affinity subtype-selective agonist ligandfor the thyroid hormone receptor. Chem. Biol., 1998, 5, 299-306.
26. Whitfield, G. K.; Jurutka, P. W.; Haussler, C. A.; Haussler, M. R.Steroid hormone receptors: evolution, ligands and molecular basisof biologic function. J. Cell. Biochem. Suppl., 1999, 32/33, 110-122.
27. Egea, P. F.; Klaholz, B. P.; Moras, D. Ligand-protein interactionsin nuclear receptors of hormones. FEBS Lett., 2000, 476, 62-67.
28. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engström, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in theoestrogen receptor. Nature, 1997, 389, 753-758.
29. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J.E.; McKee, D.D.; Galardi, C.M.; Plunket, K.D.; Nolte, R.T.; Parks, D.J.; Moore, J.T.; Kliewer, S.A.; Willson, T.M.; Stimmel, J.B. Structuralbasis for antagonist-mediated recruitmentof nuclear co-repressors by PPARα. Nature, 2002, 415, 813-817.
30. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interactionby tamoxifen. Cell, 1995, 95, 927-937.
31. Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R.Structure and specificity of nuclear receptor-coactivator interactions.G&D, 1998, 12, 3343-3356.
32. Hur, E.; Pfaff, S. J.; Payne, E. S.; Grøn, H.; Buehrer, B. M.; Fletterick, R. J. Recognition and Accommodation at the Androgen ReceptorCoactivator Binding Interface. PLoS Biol., 2004, 2, 1303-1312.
33. www.pdb.org
34. Togashi, M.; Borngraeber, S.; Sandler, B.; Fletterick, R. J.; Webb, P.; Baxter, J. D. Conformational adaptation of nuclear receptorligand binding domains to agonists: Potential for novel approachesto ligand design. J. Steroid Biochem. Mol. Biol., 2005, 93, 127-137.
35. Wagner, R. L.; Apriletti, M. E.; McGrath, M. E.; West, B. L.; Baxter, J. D.; Fletterick, R. J. A structural role for hormone in the thyroidhormone receptor. Nature, 1995, 378, 690-697.
36. Nettless, K. W.; Greene, G. L. Ligand control of coregulator recruitmentof nuclear receptor. Annu. Rev. Physiol., 2004.
37. Nolte, R. T.; Wisely, G. B.; Wstin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Wilson, T. M., Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisomeproliferator-activated receptor gamma. Nature, 1998, 395, 137-143.
38. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Wilson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: structuraldeterminants of directed promiscuity. Science, 2001, 292, 2329-2333.
39. Kenny, P.W. Mechanism of and rogen receptor action. Maturitas, 2009, 63, 142-148.
40. Heinlein, C. A.; Chang, C. Androgen receptor in prostate cancer.Endocr. Rev., 2004, 25, 276-308.
41. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An Y.; Wu, G. Y.; Scheer, J. E.; Salvati, M. E.; Krystek, Jr., S. R.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of theligand-binding domains of the and rogen receptor and its T877Amutant complexed with the natural agonist dihydrotestosterone.Proc. Natl. Acad. Sci. USA, 1998, 101, 4904-4909.
42. Huggins C. Two principles in endocrine therapy of cancers: hormonedeprival and hormone interference. Cancer Res., 1965, 25, 1163-1167.
43. Denis, L. J.; Griffiths, K. Endocrine treatment in prostate cancer.Semin. Surg. Oncol., 2000, 18, 52-74.
44. Fang, H.; Tong, W.; Branham, W. S.; Moland, C. L.; Dial, S. L.; Hong, H.; Xie, Q.; Perkins, R.; Owens, W.; Sheehan, D. M. Studyof 202 natural, synthetic, and environmental chemicals for bindingto the and rogen receptor. Chem. Res. Toxicol., 2003, 16, 1338-1358.
45. Dalton, J. T.; Mukherjee, A.; Zhu, Z.; Kirkovsky, L.; Miller, D. D.Discovery of nonsteroidal and rogens. Biochem. Biophy. Res. Commun., 1998, 244, 1-4.
46. Lill, M. A.; Winiger, F.; Vedani, A.; Ernst, B. Impact of induced fiton ligand binding to the and rogen receptor: a multidimensionalqsar study to predict endocrine-disrupting effects of environmentalchemicals. J. Med. Chem., 2005, 48, 5666-5674.
47. Cantin, L.; Faucher, F.; Couture, J.-F.; Pereira de Jesus-Tran, K.; Legrand, P.; Ciobanu, L. C.; Frechette, Y.; Labrecque, R.; Singh, S.M.; Labrie, F.; Breton, R. Structural characterization of the humanandrogen receptor ligand-binding domain complexed withEM5744, a rationally designed steroidal ligand bearing a bulkychain directed toward helix 12. J. Biol. Chem., 2007, 282, 30910-30919.
48. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structuralbasis for accommodation of nonsteroidal ligands in the and rogenreceptor. J. Biol. Chem., 2005, 280, 37747-37754.
49. Pereira de Jesus-Tran, K.; Cote, P. L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. Comparison of crystal structures of humanandrogen receptor ligand-binding domain complexed with variousagonists reveals molecular determinants responsible for binding affinity.Protein Sci., 2006, 15, 987-999.
50. Bohl, C. E.; Wu, Z.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Crystalstructure of the t877a human and rogen receptor ligand-binding domaincomplexed to cyproterone acetate provides insight for ligandinduced conformational changes and structure-based drug design.J. Biol. Chem., 2008, 282, 13648-13655.
51. Bisson, W. H.; Abagyan, R.; Cavasotto, C. N. Molecular basis of agonicity and antagonicity in the and rogen receptor studiedby moleculardynamics simulations. J. Mol. Graph. Model., 2008, 27, 452-458.
52. Kuil, C. W.; Berrevoets, C. A.; Mulder, E. Ligand-induced conformationalalterations of the and rogen receptor analyzed by limitedtrypsinization. J. Biol. Chem., 1995, 270, 27569-27576.
53. Kallio, P. J.; Janne, O. A.; Palvimo, J. J. Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. Endocrinology, 1994, 134, 998-1001.
54. Tsai, M.-J.; O'Malley, B. W. Molecular mechanism of action of steroid/thyroid receptor superfamily members. Annu. Rev., 1994, 63, 451-486.
55. Lill, M. A.; Winiger, F.; Vedani, A.; Ernst. B. Impact of induced fiton ligand binding to the and rogen receptor: a multidimensionalqsar study to predict endocrine-disrupting effects of environmentalchemicals. J. Med. Chem., 2005, 48, 5666-5674.
56. Zhou, J.; Cidlowski, J. A. The human glucocorticoid receptor: Onegene, multiple proteins and diverse responses. Steroids, 2005, 70, 407-417.
57. Nicolaidesa, N. C.; Galataa, Z.; Kinob, T.; Chrousosa, G. P.; Charmandari, E. The human glucocorticoid receptor: Molecular basisof biologic function, Steroids, 2010, 75, 1-12.
58. Chrousos, G. P., Charmandari, E.; Kino, T. Glucocorticoid actionnetworks-anintroduction to systems biology. J. Clin. Endocrinol.Metab., 2004, 89, 563-564.
59. Chrousos, G. P. The glucocorticoid receptor gene, longevity, and the complexdisorders of Western societies. Am. J. Med., 2004, 117, 204-207.
60. Galon, J.; Franchimont, D.; Hiroi, N.; Frey, G.; Boettner, A.; Ehrhart-Bornstein, M.; O'Shea, J.J.; Chrousos, G.P.; Bornstein, S.R.Gene profiling reveals unknown enhancing and suppressive actionsof glucocorticoids on immune cells. FASEB J., 2002, 16, 61-71.
61. Clark, J. K.; Schrader, W. T.; O'Malley, B. W. In: Mechanism of Steroid Hormones; Williams textbook of endocrinology; Wilson, J.D.; Foster, D. W.; Eds; WB Saunders Co: Philadelphia, 1992, pp35-90.
62. Tanaka, H.; Yoshikawa, N.; Shimizu, N.; Morimoto, C. Selectivemodulation of glucocorticoid receptor function toward developmentof novel antiinflammation: lessons from a phenylpyrazolosteroidcortivazol. Mod. Rheumatol., 2004, 14, 347-355.
63. Adcock, I. M. Glucocorticoids: new mechanisms and future agents.Curr. Allergy Asthma Rep., 2003, 3, 249-257.
64. Bledsoe, R. K.; Montana, V. G.; Stanley, T. B.; Delves, C. J.; Apolito, C. J.; McKee, D. D.; Consler, T.G.; Parks, D.J.; Stewart, E.L.; Willson, T.M.; Lambert, M.H.; Moore, J.T.; Pearce, K.H.; Xu, H.E, Crystal structure of the glucocorticoid receptorligandbinding domain reveals a novel mode of receptor dimerizationandcoactivator recognition. Cell, 2002, 110, 93-105.
65. Schlechte, J. A.; Simons, Jr. S. S.; Lewis, D. A.; Thompson, E. B. [3H] cortivazol: a unique high affinity ligand for the glucocorticoidreceptor. Endocrinology, 1998, 117, 1355-1362.
66. Geller, D. S.; Farhi, A.; Pinkerton, N.; Fradley, M.; Moritz, M.; Spitzer, A.; Meinke, G.; Tsai, F.T.; Sigler, P.B.; Lifton, R.P. Activatingmineralocorticoid receptor mutation in hypertension exacerbatedby pregnancy. Science, 2000, 289, 119-123.
67. Simons, S. S. Jr.; Thompson, E. B.; Johnson, D. F. Antiinflammatorypyrazolo-steroids: potent glucocorticoids containingbulky A-ring substituents and no C3-carbonyl. Biochem. Biophys.Res. Commun., 1979, 86, 792-800.
68. Thompson, E. B.; Srivastava, D.; Johnson, B. H. Interactions of thephenylpyrazolo steroid cortivazol with glucocorticoid receptors insteroidsensitive and -resistant human leukemic cells. Cancer Res., 1989, 49, 2253-2258.
69. Suino-Powell, K.; Xu, Y.; Zhang, C.; Tao, Y.-Q.; Tolbert, W.-D.; Simons, S. S. Jr.; Xu, H. E. Doubling the size of the glucocorticoidreceptor ligand binding pocket by deacylcortivazol. Mol. Cell.Biol., 2008, 28, 1915-1923.
70. Wanga, H.; Aslanian, R.; Madison, V. S. Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor17α pocket flexibility. J. Mol. Graph. Model., 2008, 27, 512-521.
71. Hammer, S.; Spika, I.; Sippl, W.; Jessen, G.; Kleuser, B.; Höltje, H.-D.; Schäfer-Korting, M. Glucocorticoid receptor interactionswith glucocorticoids: evaluation by molecular modeling and functionalanalysis of glucocorticoid receptor mutants. Steroids. 2003, 68, 329-339.
72. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in theoestrogen receptor. Nature, 1997, 387, 753-758.
73. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographiccomparison of the estrogen and progesterone receptor'sligand binding domains. Proc. Natl. Acad. Sci USA, 1998, 95, 5998-6003.
74. Rosati, R. L.; Jardine, P. D. S.; Cameron, K. O.; Thompson, D.D.; Ke, H. Z.; Toler, S.M.; Brown, T.A.; Pan, L.C.; Ebbinghaus, C.F.; Reinhold, A.R.; Elliott, N.C.; Newhouse, B.N.; Tjoa, C.M.; Sweetnam, P.M.; Cole, M.J.; Arriola, M.W.; Gauthier, J.W.; Crawford, D.T.; Nickerson, D.F.; Pirie, C.M.; Qi, H.; Simmons, H.A.; Tkalcevic, G.T. Discovery and preclinical pharmacology of anovel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem., 1998, 41, 2928-2931.
75. Dutertre, M.; Smith, C. L. Molecular mechanisms of selectiveestrogen receptor modulator (SERM) action. J. Pharmacol. Exp.Ther., 2000, 295, 431-437.
76. Schwartz, J. A.; Skafar, D. F. Ligand-mediated modulation of estrogen receptor conformation by estradiolanalogs. Biochemistry., 1993, 32, 10109-10115.
77. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogenreceptor beta in the presence of a partial agonist and a full antagonis.EMBO J., 1999, 18, 4608-4618.
78. Zeng, J.; Li, W.; Zhao, Y.; Liu, G.; Tang, Y.; Jiang, H. Insights intoligand selectivity in estrogen receptor isoforms: molecular dynamicssimulations and binding free energy calculations. J. Phys.Chem. B, 2008, 112, 2719-2726.
79. Manas, E. S.; Unwalla, R. J.; Xu, Z. B.; Malamas, M. S.; Miller, C.P.; Harris, H. A.; Hsiao, C.; Akopian, T.; Hum, W. T.; Malakian, K.; Wolfrom, S.; Bapat, A.; Bhat, R.A.; Stahl, M.L.; Somers, W.S.; Alvarez, J.C. Structure-based design of estrogen receptor-beta selectiveligands. J. Am. Chem. Soc., 2004, 126, 15106-15119.
80. Celik, L.; Lund, J. D. D.; Schiøtt, B. Conformational dynamics of the estrogen receptor r: molecular dynamics simulations of the influenceof binding site structure on protein dynamics. Biochemistry, 2007, 46, 1743-1758.
81. McGee, T. D.; Edwards, J.; Roitberg, A. E. Preliminary moleculardynamic simulations of the estrogen receptor alpha ligand bindingdomain from antagonist to apo. Int. J. Environ. Res. Public, 2008, 5, 111-114.
82. Ellmann, S.; Sticht, H.; Thiel, F.; Beckmann, M. W.; Strick, R.; Strissel, P. L. Estrogen and progesterone receptors: from molecularstructuresto clinical targets. Cell. Mol. Life Sci., 2009, 66, 2405-2426.
83. Lydon, J. P.; DeMayo, F. J.; Funk, C. R.; Mani, S. K.; Hughes, A.R; Montgomery, C. A. Jr; Shyamala, G.; Conneely, O. M.; O'Malley, B. W. Mice lacking progesterone receptor exhibit pleiotropicreproductiveabnormalities. Genes Dev., 1995, 9, 2266-2278.
84. Philibert, D.; Deraedt, R.; Teutsch, G. RU 38486: a potent antiglucocorticoidin vivo. In Proceedings of the VII International Congressof Pharmacology, Tokyo, 1981.
85. Raaijmakers, H.; Versteegh, J. E.; Uitdehaag, J. C. M. The x-raystructure of ru486 bound to the progesterone receptor in a destabilizedagonistic conformation. J. Biol. Chem., 2009, 284, 19572-19579.
86. Letz, M.; Bringmann, P.; Mann, M.; Mueller-Fahrnow, A.; Reipert, D.; Scholz, P.; Wurtz, J. M.; Egner, U. Investigation of the bindinginteractions of progesterone using muteins of the human progesteronereceptor ligand binding domain designed on the basis of athree-dimensional protein model. Biochim. Biophy. Acta, 1999, 1429, 391-400.
87. Nettles, K. W.; Bruning, J. B.; Gil, G.; Nowak, J.; Sharma, S. K.; Hahm, J. B.; Kulp, K.; Hochberg, R. B.; Zhou, H.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Kim, Y.; Joachmiak, A.; Greene, G. L. NFκB selectivity of estrogen receptor ligands revealedby comparative crystallographic analyses. Nat. Chem. Biol., 2008, 4, 241-247.
88. Madauss, K. P.; Deng, S.-J.; Austin, R. J. H.; Lambert, M. H.; McLay, I.; Pritchard, J.; Short, S. A.; Stewart, E. L.; Uings, I. J.; Williams, S. P. Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoatecomplexes. J. Med. Chem., 2004, 47, 3381-3387.